Segment Information

6 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

We have three reporting segments: Clinical Research Services (“CRS”), PAREXEL Consulting and Medical Communication Services (“PCMS”), and Perceptive Informatics (“Perceptive”).

• CRS constitutes our core business and includes all phases of clinical research from Early Phase (encompassing the early stages of clinical testing that range from first-in-man through proof-of-concept studies) to Phase II-III and Phase IV, which we call Peri-Approval Clinical Excellence (“PACE”). Our services include clinical trials management and biostatistics, data management and clinical pharmacology, as well as related medical advisory, patient recruitment, clinical supply and drug logistics, pharmacovigilance, and investigator site services. We aggregate Early Phase with Phase II-III/PACE due to economic similarities in these operating segments.

• PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance. It also provides a full spectrum of market development, product development, and targeted communications services in support of product launch. Our PCMS consultants identify alternatives and propose solutions to address client issues associated with product development, registration, and commercialization.

• Perceptive provides information technology solutions designed to help improve clients’ product development and regulatory submission processes. Perceptive offers a portfolio of products and services that includes medical imaging services, ClinPhone^® randomization and trial supply management ("RTSM"), IMPACT^® clinical trials management systems ("CTMS"), DataLabs^® electronic data capture ("EDC"), web-based portals, systems integration, electronic patient reported outcomes ("ePRO"), and Liquent InSight® Regulatory Information Management (RIM) platform. These services are often bundled together and integrated with other applications to provide eClinical solutions for our clients.

We evaluate our segment performance and allocate resources based on service revenue and gross profit (service revenue less direct costs), while other operating costs are allocated and evaluated on a geographic basis. Accordingly, we do not include the impact of selling, general, and administrative expenses, depreciation and amortization expense, other income (expense), and income tax expense in segment profitability. We attribute revenue to individual countries based upon the revenue earned in the respective countries; however, inter-segment transactions are not included in service revenue. Furthermore, PAREXEL has a global infrastructure supporting its business segments, and therefore, assets are not identified by reportable segment.

Our segment results are as follows:

(in thousands)	Three Months Ended				Six Months Ended
	December 31, 2012		December 31, 2011		December 31, 2012		December 31, 2011
Service revenue
CRS	$	320,580	$	247,871	$	617,747	$	483,280
PCMS	49,274		38,455		97,625		74,103
Perceptive	52,214		46,844		101,449		90,522
Total service revenue	$	422,068	$	333,170	$	816,821	$	647,905
Direct costs
CRS	$	242,415	$	177,841	$	462,581	$	350,591
PCMS	28,454		22,584		58,139		43,562
Perceptive	30,456		27,674		60,009		56,120
Total direct costs	$	301,325	$	228,099	$	580,729	$	450,273
Gross profit
CRS	$	78,165	$	70,030	$	155,166	$	132,689
PCMS	20,820		15,871		39,486		30,541
Perceptive	21,758		19,170		41,440		34,402
Total gross profit	$	120,743	$	105,071	$	236,092	$	197,632